Scientific Accomplishments

Scientific Accomplishments

Selected highlights from Program members:

  • The Ruggero lab showed that Myc-induced lymphomas can be suppressed by simply reducing rates of protein synthesis in vivo, suggesting protein translation is a target for therapeutic intervention (Barna et al., Nature, 2008).

  • Dr. Müschen and colleagues showed that targeted inhibition of BCL6 eradicates drug-resistant and leukemia-initiating cells (Duy et al., Nature, 2011).

  • Dr. Shah and colleagues compared clinical responses to dasatanib and imatanib in patients suffering from CML, and showed that desatanib is superior (Kantarjian et al., N Engl J Med, 2010).

  • Dr. Shannon’s group, collaborating with Dr. Scott Kogan, reported that AML cells are more responsive to MEK inhibitors than their less aggresive precursors, but soon become resistant through several distinct mechanisms (Lauchle et al., Nature, 2009).

  • Dr. Passegue discovered that hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis (Lauchle et al., Nature, 2009).

  • Drs. Rubenstein, Damon, and colleagues showed in a phase I study that intrathecal rituximab is a feasible and effective treatment for non-hodgkin’s lymphoma with CNS involvement (Rubenstein et al., J Clin Oncol, 2007).